Fistulizing crohn’s disease: Diagnosis and management

United European Gastroenterology Journal

Volumn 1, Issue 3, 2013, Pages 206-213

  Gecse, Krisztina ^a,b   Khanna, Reena ^c   Stoker, Jaap ^a   Jenkins, John T ^d   Gabe, Simon ^d   Hahnloser, Dieter ^e   D’Haens, Geert ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b European Division   (Netherlands)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d ST MARK S HOSPITAL   (United Kingdom)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Anti TNF therapy; Crohn s disease; Enterocutaneous fistula; Inflammatory bowel disease; Perianal fistula

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB;

ANESTHESIA; ANUS FISTULA; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC ACCURACY; ENDOSCOPIC ECHOGRAPHY; ENTEROCUTANEOUS FISTULA; FISTULIZING CROHN DISEASE; FISTULOGRAPHY; META ANALYSIS (TOPIC); MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85006181412     PISSN: 20506406     EISSN: 20506414     Source Type: Journal    
DOI: 10.1177/2050640613487194     Document Type: Article

References (62)

1. Sandborn WJ, Fazio VW, Feagan BG and Hanauer SB. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003; 125(5): 1508–1530.
2. Schwartz DA, Loftus Jr EV, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002; 122(4): 875–880.
3. Hellers G, Bergstrand O, Ewerth S and Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn’s disease. Gut 1980; 21: 525–527.
4. Hughes LE. Surgical pathology and management of anorectal Crohn’s disease. J R Soc Med 1978; 71: 644–651.
5. Poritz LS, Gagliano GA, McLeod RS, MacRae H and Cohen Z. Surgical management of entero and colocutaneous fistulae in Crohn’s disease: 17 year’s experience. Int J Colorectal Dis 2004; 19(5): 481–485.
6. Parks AG, Gordon PH and Hardcastle JD. A classification of fistula-in-ano. Br J Surg 1976; 63(1): 1–12.
7. Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20(1): 27–32.
8. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, Van Hogezand RA, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340(18): 1398–1405.
9. Van AG, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol 2003; 98(2): 332–339.
10. Halligan S and Bartram CI. MR imaging of fistula in ano: are endoanal coils the gold standard? AJR Am J Roentgenol 1998; 171(2): 407–412.
11. Horsthuis K, Lavini C, Bipat S, Stokkers PC and Stoker J. Perianal Crohn disease: evaluation of dynamic contrast- enhanced MR imaging as an indicator of disease activity. Radiology 2009; 251(2): 380–387.
12. Orsoni P, Barthet M, Portier F, Panuel M, Desjeux A and Grimaud JC. Prospective comparison of endosonography, magnetic resonance imaging and surgical findings in anorectal fistula and abscess complicating Crohn’s disease. Br J Surg 1999; 86(3): 360–364.
13. Schwartz DA, Wiersema MJ, Dudiak KM, Fletcher JG, Clain JE, Tremaine WJ, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn’s perianal fistulas. Gastroenterology 2001; 121(5): 1064–1072.
14. Sahni VA, Ahmad R and Burling D. Which method is best for imaging of perianal fistula? Abdom Imaging 2008; 33: 26–30.
15. Ziech M, Felt-Bersma R and Stoker J. Imaging of perianal fistulas. Clin Gastroenterol Hepatol 2009; 7: 1037–1045.
16. Buchanan G, Halligan S, Williams A, Cohen CR, Tarroni D, Phillips RK, et al. Effect of MRI on clinical outcome of recurrent fistula-in-ano. Lancet 2002; 360(9346): 1661–1662.
17. Bernstein LH, Frank MS, Brandt LJ and Boley SJ. Healing of perineal Crohn’s disease with metronidazole. Gastroenterology 1980; 79(2): 357–365.
18. Brandt LJ, Bernstein LH, Boley SJ and Frank MS. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982; 83(2): 383–387.
19. Thia KT, Mahadevan U, Feagan BG, Wong C, Cockeram A, Bitton A, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn’s disease: a randomized, double-blind, placebocontrolled pilot study. Inflamm Bowel Dis 2009; 15(1): 17–24.
20. Jakobovits J and Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984; 79(7): 533–540.
21. Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H and Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn’s disease. Aliment Pharmacol Ther 2003; 18: 1113–1120.
22. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB and Pasternack BS. Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, doubleblind study. N Engl J Med 1980; 302: 981–987.
23. Pearson DC, May GR, Fick GH and Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123(2): 132–142.
24. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, et al. Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125(2): 380–388.
25. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 48–63.
26. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350(9): 876–885.
27. West RL, van der Woude CJ, Hansen BE, Felt-Bersma RJ, van Tilburg AJ, Drapers JA, et al. Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn’s disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther 2004; 20(11–12): 1329–1336.
28. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132(1): 52–65.
29. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 2007; 357(3): 228–238.
30. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357(3): 239–250.
31. Scott HJ and Northover JM. Evaluation of surgery for perianal Crohn’s fistulas. Dis Colon Rectum 1996; 39(9): 1039–1043.
32. Halme L and Sainio AP. Factors related to frequency, type, and outcome of anal fistulas in Crohn’s disease. Dis Colon Rectum 1995; 38(1): 55–59.
33. van Onkelen RS, Gosselink MP and Schouten WR. Ligation of the intersphincteric fistula tract in low transsphincteric fistula: A new technique to avoid fistulotomy. Colorectal Dis. Epub ahead of print 13 September 2012.
34. Soltani A and Kaiser AM. Endorectal advancement flap for cryptoglandular or Crohn’s fistula-in-ano. Dis Colon Rectum 2010; 53(4): 486–495.
35. Ellis CN, Rostas JW and Greiner FG. Long-term outcomes with the use of bioprosthetic plugs for the management of complex anal fistulas. Dis Colon Rectum 2010; 53(5): 798–802.
36. Chung W, Ko D, Sun C, Raval MJ, Brown CJ and Phang PT. Outcomes of anal fistula surgery in patients with inflammatory bowel disease. Am J Surg 2010; 199(5): 609–613.
37. O’Connor L, Champagne BJ, Ferguson MA, Orangio GR, Schertzer ME and Armstrong DN. Efficacy of anal fistula plug in closure of Crohn’s anorectal fistulas. Dis Colon Rectum 2006; 49(10): 1569–1573.
38. Schwandner O, Stadler F, Dietl O, Wirsching RP and Fuerst A. Initial experience on efficacy in closure of cryptoglandular and Crohn’s transsphincteric fistulas by the use of the anal fistula plug. Int J Colorectal Dis 2008; 23(3): 319–324.
39. Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Senejoux A, Vitton V, et al. Fibrin glue is effective healing perianal fistulas in patients withCrohn’s disease. Gastroenterology 2010; 138(7): 2275–2281.
40. Ellis CN and Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. Dis Colon Rectum 2006; 49(11): 1736–1740.
41. Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C and Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005; 48(7): 1416–1423.
42. Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del- Valle E, Zorrilla J, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52(1): 79–86.
43. Ciccocioppo R, Bernardo ME, Sgarella A, Maccario R, Avanzini MA, Ubezio C, et al. Autologous bone marrowderived mesenchymal stromal cells in the treatment of fistulising Crohn’s disease. Gut 2011; 60(6): 788–798.
44. Colombel JF, Loftus Jr EV, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients withCrohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99(5): 878–883.
45. Wallaert JB, De Martino RR, Marsicovetere PS, Goodney PP, Finlayson SR, Murray JJ, et al. Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum 2012; 55(11): 1138–1144.
46. Martinez D, Zibari G, Aultman D, McMillan R, Mancini MC, Rush BM, et al. The outcome of intestinal fistulae: the Louisiana State University Medical Center– Shreveport experience. Am Surg 1998; 64(3): 252–254.
47. Mawdsley JE, Hollington P, Bassett P, Windsor AJ, Forbes A and Gabe SM. An analysis of predictive factors for healing and mortality in patients with enterocutaneous fistulas. Aliment Pharmacol Ther 2008; 28(9): 1111–1121.
48. Campos AC, Andrade DF, Campos GM, Matias JE and Coelho JC. A multivariate model to determine prognostic factors in gastrointestinal fistulas. J Am Coll Surg 1999; 188(5): 483–490.
49. Hollington P, Mawdsley J, Lim W, Gabe SM, Forbes A and Windsor AJ. An 11-year experience of enterocutaneous fistula. Br J Surg 2004; 91(12): 1646–1651.
50. Lloyd DA, Gabe SM and Windsor AC. Nutrition andmanagement of enterocutaneous fistula. Br J Surg 2006; 93(9): 1045–1055.
51. Levy E, Frileux P, Cugnenc PH, Honiger J, Ollivier JM and Parc R. High-output external fistulae of the small bowel: management with continuous enteral nutrition. Br J Surg 1989; 76(7): 676–679.
52. Li J, Ren J, Zhu W, Yin L and Han J. Management of enterocutaneous fistulas: 30-year clinical experience. Chin Med J (Engl) 2003; 116(2): 171–175.
53. Teubner A, Morrison K, Ravishankar HR, Anderson ID, Scott NA and Carlson GL. Fistuloclysis can successfully replace parenteral feeding in the nutritional support of patients with enterocutaneous fistula. Br J Surg 2004; 91(5): 625–631.
54. Hesse U, Ysebaert D and de HB. Role of somatostatin-14 and its analogues in the management of gastrointestinal fistulae: clinical data. Gut 2001; 49(Suppl 4): 11–21.
55. Rahbour G, Siddiqui MR, Ullah MR, Gabe SM, Warusavitarne J and Vaizey CJ. A Meta-analysis of outcomes following use of somatostatin and its analogues for the management of enterocutaneous fistulas. Ann Surg 2012; 256(6): 946–954.
56. Gabe SM, Shaffer JL, Forbes A, Holst M, Irtun O, Klek S, et al. The management of patients with high output enterocutaneous fistulae: a European survey. Clin Nutr 2012; 7(14): 33.
57. Poritz LS, Rowe WA and Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum 2002; 45(6): 771–775.
58. Fries W, La MG, Costantino G, Repici A, Mazziotti S and Navarra G. Combined approach with biologics and surgery for enterocutaneous fistulas in Crohn’s disease. Inflamm Bowel Dis 2011; 17(2): 671–673.
59. Lynch AC, Delaney CP, Senagore AJ, Connor JT, Remzi FH and Fazio VW. Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery. Ann Surg 2004; 240(5): 825–831.
60. Taner T, Cima RR, Larson DW, Dozois EJ, Pemberton JH and Wolff BG. Surgical treatment of complex enterocutaneous fistulas in IBD patients using human acellular dermal matrix. Inflamm Bowel Dis 2009; 15(8): 1208–1212.
61. Datta V, Engledow A, Chan S, Forbes A, Cohen CR and Windsor A. The management of enterocutaneous fistula in a regional unit in the United Kingdom: a prospective study. Dis Colon Rectum 2010; 53(2): 192–199.
62. Garcia-Olmo D, Herreros D, Pascual M, Pascual I, De La Quintana P, Trebol J, et al. Treatment of enterocutaneous fistula in Crohn’s Disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int J Colorectal Dis 2009; 24(1): 27–30.